| 1 |
Leung RKC, Leung HC, Leung AYH. Diverse pathogenetic roles of SOX genes in acute myeloid leukaemia and their therapeutic implications[J]. Seminars in cancer biology, 2020, 67(1): 24-29.
|
| 2 |
Jin S, Cojocari D, Purkal JJ, et al. 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis[J]. Clin Cancer Res, 2020, 26(13): 3371-3383.
|
| 3 |
王昱，黄晓军. 单倍型移植治疗中高危急性髓系白血病第一次缓解期：指南与实践[J]. 中华血液学杂志，2016, 37(8): 721-724.
|
| 4 |
Pourrajab F, Zare-Khormizi MR, Hashemi AS, et al. Genetic characterization and risk stratification of acute myeloid leukemia[J]. Cancer Manag Res, 2020, 12: 2231-2253.
|
| 5 |
Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence[J]. Lekumia, 2019, 33(2): 299-312.
|
| 6 |
Sun YM, Wang WT, Zeng ZC, et al. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression[J]. Blood, 2019, 134(18): 1533-1546.
|
| 7 |
Lachowiez CA, Loghavi S, Kadia TM, et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens[J]. Blood Adv, 2020, 4(7): 1311-1320.
|
| 8 |
Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia[J]. Blood, 2016, 128(5): 686-698.
|
| 9 |
Spencer DH, Russler-Germain DA, Ketkar S, et al. CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression[J]. Cell, 2017, 168(5): 801-816.
|
| 10 |
唐善浩，陆滢，张丕胜，等. FLT3-ITD与DNMT3A R882双突变对急性髓系白血病异基因造血干细胞移植预后的影响[J]. 中华血液学杂志，2018, 39(7): 552-557.
|
| 11 |
Mannelli F, Ponziani V, Bencini S, et al. CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features[J]. Haematologica, 2017, 102(3): 529-540.
|
| 12 |
裴荣荣，张荣辉，于吉峰，等. FLT3-ITD及CEBPA基因共突变成人急性髓系白血病患者的临床特征及预后分析[J]. 中华血液学杂志，2020, 41(4): 297-299.
|
| 13 |
Kakosaiou K, Panitsas F, Daraki A, et al. ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics[J]. Leuk Lymphoma, 2018, 59(10): 2439-2446.
|
| 14 |
陈梅玉，刘洁，晁红颖，等. 骨髓增生异常综合征患者的ASXL1基因变异分析[J]. 中华医学遗传学杂志，2020, 37(2): 110-115.
|
| 15 |
Cazzola A, Schlegel C, Jansen I, et al. TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia[J]. Leukemia, 2019, 33(11): 2619-2627.
|
| 16 |
Welch JS. Patterns of mutations in TP53 mutated AML[J]. Best Pract Res Clin Haematol, 2018, 31(4): 379-383.
|
| 17 |
Aldoss I, Zhang J, Pillai R, et al. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia[J]. Br J Haematol, 2019, 187(2): 45-48.
|
| 18 |
中华医学会血液学分会白血病淋巴瘤学组. 复发难治性急性髓系白血病中国诊疗指南(2017年版)[J]. 中华血液学杂志，2017, 38(3): 183-184.
|
| 19 |
艾昊，符粤文，王勇琪，等. 含克拉屈滨预处理方案异基因造血干细胞移植治疗12例难治/复发急性髓系白血病临床观察[J]. 中华血液学杂志，2019, 40(10): 827-830.
|
| 20 |
张钰，宣丽，范志平，等. 索拉菲尼作为挽救性治疗在难治复发性FLT3突变阳性急性髓系白血病中的临床应用研究[J]. 中华血液学杂志，2016, 37(4): 292-296.
|
| 21 |
Jamil MO, Mineishi S. State-of-the-art acute and chronic GVHD treatment[J]. Int J Hematol, 2015, 101(5): 452-466.
|